Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.

Azorsa DO, Lee DW, Wai DH, Bista R, Patel AR, Aleem E, Henry MM, Arceci RJ.

Pediatr Blood Cancer. 2018 Sep;65(9):e27237. doi: 10.1002/pbc.27237. Epub 2018 May 16.

PMID:
29768711
2.

Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.

Bista R, Lee DW, Pepper OB, Azorsa DO, Arceci RJ, Aleem E.

J Exp Clin Cancer Res. 2017 Feb 1;36(1):22. doi: 10.1186/s13046-017-0493-5.

3.

Data Analysis for High-Throughput RNAi Screening.

Azorsa DO, Turnidge MA, Arora S.

Methods Mol Biol. 2016;1470:247-60. doi: 10.1007/978-1-4939-6337-9_19.

PMID:
27581298
4.

Optimization of Transfection Conditions for siRNA Screening.

Montoya JJ, Azorsa DO.

Methods Mol Biol. 2016;1470:15-24. doi: 10.1007/978-1-4939-6337-9_2.

PMID:
27581281
5.

Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma.

Bogen D, Wei JS, Azorsa DO, Ormanoglu P, Buehler E, Guha R, Keller JM, Mathews Griner LA, Ferrer M, Song YK, Liao H, Mendoza A, Gryder BE, Sindri S, He J, Wen X, Zhang S, Shern JF, Yohe ME, Taschner-Mandl S, Shohet JM, Thomas CJ, Martin SE, Ambros PF, Khan J.

Oncotarget. 2015 Nov 3;6(34):35247-62. doi: 10.18632/oncotarget.6208.

6.

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary A, Valdez R, Camoriano J, Fauble V, Tiedemann RE, Qiu YH, Coombes KR, Cardone M, Braggio E, Yin H, Azorsa DO, Mesa RA, Stewart AK, Tibes R.

Leukemia. 2014 Aug;28(8):1657-65. doi: 10.1038/leu.2014.44. Epub 2014 Jan 23.

7.

High-throughput RNAi screening for the identification of novel targets.

Henderson MC, Azorsa DO.

Methods Mol Biol. 2013;986:89-95. doi: 10.1007/978-1-62703-311-4_6.

PMID:
23436407
8.

Negative regulation of NF-κB by the ING4 tumor suppressor in breast cancer.

Byron SA, Min E, Thal TS, Hostetter G, Watanabe AT, Azorsa DO, Little TH, Tapia C, Kim S.

PLoS One. 2012;7(10):e46823. doi: 10.1371/journal.pone.0046823. Epub 2012 Oct 4.

9.

BIRC5 expression is a poor prognostic marker in Ewing sarcoma.

Hingorani P, Dickman P, Garcia-Filion P, White-Collins A, Kolb EA, Azorsa DO.

Pediatr Blood Cancer. 2013 Jan;60(1):35-40. doi: 10.1002/pbc.24290. Epub 2012 Sep 7.

PMID:
22961763
10.

Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: a paradigm shift that impacts current therapeutic strategies.

Marlow LA, von Roemeling CA, Cooper SJ, Zhang Y, Rohl SD, Arora S, Gonzales IM, Azorsa DO, Reddi HV, Tun HW, Döppler HR, Storz P, Smallridge RC, Copland JA.

J Cell Sci. 2012 Sep 15;125(Pt 18):4253-63. doi: 10.1242/jcs.097428. Epub 2012 Jun 20.

11.

The genomic and proteomic content of cancer cell-derived exosomes.

Henderson MC, Azorsa DO.

Front Oncol. 2012 Apr 17;2:38. doi: 10.3389/fonc.2012.00038. eCollection 2012.

12.

RNAi screening of the kinome with cytarabine in leukemias.

Tibes R, Bogenberger JM, Chaudhuri L, Hagelstrom RT, Chow D, Buechel ME, Gonzales IM, Demuth T, Slack J, Mesa RA, Braggio E, Yin HH, Arora S, Azorsa DO.

Blood. 2012 Mar 22;119(12):2863-72. doi: 10.1182/blood-2011-07-367557. Epub 2012 Jan 20.

PMID:
22267604
13.

High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells.

Henderson MC, Gonzales IM, Arora S, Choudhary A, Trent JM, Von Hoff DD, Mousses S, Azorsa DO.

Mol Cancer Res. 2011 Jun;9(6):724-32. doi: 10.1158/1541-7786.MCR-10-0436. Epub 2011 May 2.

14.

NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells.

Savas S, Azorsa DO, Jarjanazi H, Ibrahim-Zada I, Gonzales IM, Arora S, Henderson MC, Choi YH, Briollais L, Ozcelik H, Tuzmen S.

PLoS One. 2011 Apr 4;6(4):e18306. doi: 10.1371/journal.pone.0018306.

15.

Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer.

Ruiz C, Holz DR, Oeggerli M, Schneider S, Gonzales IM, Kiefer JM, Zellweger T, Bachmann A, Koivisto PA, Helin HJ, Mousses S, Barrett MT, Azorsa DO, Bubendorf L.

J Pathol. 2011 Mar;223(4):543-52. doi: 10.1002/path.2828. Epub 2011 Jan 5.

PMID:
21294127
16.

Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target.

Marlow LA, D'Innocenzi J, Zhang Y, Rohl SD, Cooper SJ, Sebo T, Grant C, McIver B, Kasperbauer JL, Wadsworth JT, Casler JD, Kennedy PW, Highsmith WE, Clark O, Milosevic D, Netzel B, Cradic K, Arora S, Beaudry C, Grebe SK, Silverberg ML, Azorsa DO, Smallridge RC, Copland JA.

J Clin Endocrinol Metab. 2010 Dec;95(12):5338-47. doi: 10.1210/jc.2010-1421. Epub 2010 Sep 1. Erratum in: J Clin Endocrinol Metab. 2013 Nov;98(11):4546. J Clin Endocrinol Metab. 2013 Oct;98(10):4213.

17.

RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells.

Arora S, Bisanz KM, Peralta LA, Basu GD, Choudhary A, Tibes R, Azorsa DO.

Gynecol Oncol. 2010 Sep;118(3):220-7.

PMID:
20722101
18.

RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma.

Arora S, Gonzales IM, Hagelstrom RT, Beaudry C, Choudhary A, Sima C, Tibes R, Mousses S, Azorsa DO.

Mol Cancer. 2010 Aug 18;9:218. doi: 10.1186/1476-4598-9-218.

19.

Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer.

Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO, Yang F, Pineda M, Helman LJ, Meltzer PS.

Cancer Res. 2010 Aug 15;70(16):6497-508. doi: 10.1158/0008-5472.CAN-10-0582. Epub 2010 Jul 27.

20.

A high-content RNAi-screening assay to identify modulators of cholesterol accumulation in Niemann-Pick type C cells.

Arora S, Beaudry C, Bisanz KM, Sima C, Kiefer JA, Azorsa DO.

Assay Drug Dev Technol. 2010 Jun;8(3):295-320. doi: 10.1089/adt.2009.0240.

PMID:
20469965
21.

Chemogenomic analysis identifies Macbecin II as a compound specific for SMAD4-negative colon cancer cells.

Kaiser C, Meurice N, Gonzales IM, Arora S, Beaudry C, Bisanz KM, Robeson AC, Petit J, Azorsa DO.

Chem Biol Drug Des. 2010 Apr;75(4):360-8. doi: 10.1111/j.1747-0285.2010.00949.x.

PMID:
20331650
22.

High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation.

Azorsa DO, Robeson RH, Frost D, Meec hoovet B, Brautigam GR, Dickey C, Beaudry C, Basu GD, Holz DR, Hernandez JA, Bisanz KM, Gwinn L, Grover A, Rogers J, Reiman EM, Hutton M, Stephan DA, Mousses S, Dunckley T.

BMC Genomics. 2010 Jan 12;11:25. doi: 10.1186/1471-2164-11-25.

23.

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.

Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, Bisanz KM, Kiefer JA, Henderson MC, Trent JM, Von Hoff DD, Mousses S.

J Transl Med. 2009 Jun 11;7:43. doi: 10.1186/1479-5876-7-43.

24.

Functional evidence implicating S100P in prostate cancer progression.

Basu GD, Azorsa DO, Kiefer JA, Rojas AM, Tuzmen S, Barrett MT, Trent JM, Kallioniemi O, Mousses S.

Int J Cancer. 2008 Jul 15;123(2):330-339. doi: 10.1002/ijc.23447.

25.

Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification.

Kuuselo R, Savinainen K, Azorsa DO, Basu GD, Karhu R, Tuzmen S, Mousses S, Kallioniemi A.

Cancer Res. 2007 Mar 1;67(5):1943-9.

26.

Genome scale cytometry: High content analysis for high throughput RNAi phenotype profiling.

Evans DM, Azorsa DO, Mousses S.

Drug Discov Today Technol. 2005 Summer;2(2):141-7. doi: 10.1016/j.ddtec.2005.05.012.

PMID:
24981841
27.

Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer.

Huusko P, Ponciano-Jackson D, Wolf M, Kiefer JA, Azorsa DO, Tuzmen S, Weaver D, Robbins C, Moses T, Allinen M, Hautaniemi S, Chen Y, Elkahloun A, Basik M, Bova GS, Bubendorf L, Lugli A, Sauter G, Schleutker J, Ozcelik H, Elowe S, Pawson T, Trent JM, Carpten JD, Kallioniemi OP, Mousses S.

Nat Genet. 2004 Sep;36(9):979-83. Epub 2004 Aug 8.

PMID:
15300251
28.

Phenotypic alterations in breast cancer cells overexpressing the nuclear receptor co-activator AIB1.

Anzick SL, Azorsa DO, Simons SS Jr, Meltzer PS.

BMC Cancer. 2003 Sep 10;3:22.

29.

Activating signal cointegrator 2 belongs to a novel steady-state complex that contains a subset of trithorax group proteins.

Goo YH, Sohn YC, Kim DH, Kim SW, Kang MJ, Jung DJ, Kwak E, Barlev NA, Berger SL, Chow VT, Roeder RG, Azorsa DO, Meltzer PS, Suh PG, Song EJ, Lee KJ, Lee YC, Lee JW.

Mol Cell Biol. 2003 Jan;23(1):140-9.

30.

Association of steroid receptor coactivator AIB1 with estrogen receptor-alpha in breast cancer cells.

Azorsa DO, Cunliffe HE, Meltzer PS.

Breast Cancer Res Treat. 2001 Nov;70(2):89-101.

PMID:
11768608
31.

Endogenously expressed estrogen receptor and coactivator AIB1 interact in MCF-7 human breast cancer cells.

Tikkanen MK, Carter DJ, Harris AM, Le HM, Azorsa DO, Meltzer PS, Murdoch FE.

Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12536-40.

32.

Antibody cross-linking of human CD9 and the high-affinity immunoglobulin E receptor stimulates secretion from transfected rat basophilic leukaemia cells.

Higginbottom A, Wilkinson I, McCullough B, Lanza F, Azorsa DO, Partridge LJ, Monk PN.

Immunology. 2000 Apr;99(4):546-52.

33.

GPV is a marker of in vivo platelet activation--study in a rat thrombosis model.

Ravanat C, Freund M, Mangin P, Azorsa DO, Schwartz C, Moog S, Schuhler S, Dambach J, Cazenave JP, Lanza F.

Thromb Haemost. 2000 Feb;83(2):327-33.

PMID:
10739394
34.

CD9 participates in endothelial cell migration during in vitro wound repair.

Klein-Soyer C, Azorsa DO, Cazenave JP, Lanza F.

Arterioscler Thromb Vasc Biol. 2000 Feb;20(2):360-9.

PMID:
10669631
35.

cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene.

Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC, Pavan WJ, Trent JM, Meltzer PS.

Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13264-9.

36.
37.
38.

Measurement of GPV released by activated platelets using a sensitive immunocapture ELISA--its use to follow platelet storage in transfusion.

Azorsa DO, Moog S, Ravanat C, Schuhler S, Folléa G, Cazenave JP, Lanza F.

Thromb Haemost. 1999 Jan;81(1):131-8.

PMID:
10348704
39.

Selective tetraspan-integrin complexes (CD81/alpha4beta1, CD151/alpha3beta1, CD151/alpha6beta1) under conditions disrupting tetraspan interactions.

Serru V, Le Naour F, Billard M, Azorsa DO, Lanza F, Boucheix C, Rubinstein E.

Biochem J. 1999 May 15;340 ( Pt 1):103-11.

40.

Tetraspanin CD9 is associated with very late-acting integrins in human vascular smooth muscle cells and modulates collagen matrix reorganization.

Scherberich A, Moog S, Haan-Archipoff G, Azorsa DO, Lanza F, Beretz A.

Arterioscler Thromb Vasc Biol. 1998 Nov;18(11):1691-7.

PMID:
9812906
41.

AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.

Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS.

Science. 1997 Aug 15;277(5328):965-8.

42.

Gene cloning of rat and mouse platelet glycoprotein V: identification of megakaryocyte-specific promoters and demonstration of functional thrombin cleavage.

Ravanat C, Morales M, Azorsa DO, Moog S, Schuhler S, Grunert P, Loew D, Van Dorsselaer A, Cazenave JP, Lanza F.

Blood. 1997 May 1;89(9):3253-62.

PMID:
9129030
43.

Co-localization of CD9 and GPIIb-IIIa (alpha IIb beta 3 integrin) on activated platelet pseudopods and alpha-granule membranes.

Brisson C, Azorsa DO, Jennings LK, Moog S, Cazenave JP, Lanza F.

Histochem J. 1997 Feb;29(2):153-65.

PMID:
9147072
44.

CD9, a tetraspan transmembrane protein, renders cells susceptible to canine distemper virus.

Löffler S, Lottspeich F, Lanza F, Azorsa DO, ter Meulen V, Schneider-Schaulies J.

J Virol. 1997 Jan;71(1):42-9.

45.
46.

Characterization of a novel self-associating Mr 40,000 platelet glycoprotein.

Hildreth JE, Derr D, Azorsa DO.

Blood. 1991 Jan 1;77(1):121-32.

PMID:
1984792

Supplemental Content

Loading ...
Support Center